11 July 2017
The human epidermal growth factor receptor type 2 (HER2)-positive breast cancer market across the eight major countries of the US, France, Germany, Italy, Spain, the UK, Japan, and China, is set to rise from $6.4 billion in 2015 to $9.89 billion in 2025, representing a compound annual growth rate of 4.4%, according to research and consulting firm GlobalData.
The company’s latest report states that the adjuvant and neoadjuvant settings remain the greatest contributors to sales, with combined forecasts expected to reach $4.96 billion in 2025, representing 50% of the total HER2-positive market. This surge in market size will be driven primarily by the anticipated launch of Perjeta in the adjuvant setting, which will increase treatment duration compared to the neoadjuvant setting and protect Herceptin sales from biosimilar erosion in established markets.
Max Bourgognon, Ph.D., PharmD, Healthcare Analyst for GlobalData, explains: “The dynamism of the adjuvant and neoadjuvant markets has prompted many companies to position their products in these settings. However, many agents have failed to demonstrate clinical benefit over the currently cemented standard of care, meaning the adjuvant and neoadjuvant settings will remain an exclusive market for anti-HER2 monoclonal antibodies (mAbs), hence constituting the most lucrative opportunity for biosimilar developments.”
A new setting in HER2-positive breast cancer will be created upon the launch of Puma Biotechnology’s neratinib. GlobalData expects the drug will gain initial approval by the end of 2017 in the extended adjuvant setting, a space that is currently not utilized in the treatment of HER2-positive breast cancer, which could lead to future growth as additional companies seek to colonize this immature setting.
The analyst continues: “Although the efficacy of HER2-targeted therapies substantially improves the life expectancy of patients with HER2-positive disease, it is by nature one of the most aggressive forms of breast cancer, with a poorer prognosis and worse outcomes than for patients with HER2-negative (and HR-positive) disease.
“HER2-targeting mAbs, for example, have failed to deliver benefits to patients with brain metastases, because they cannot pass the blood-brain barrier. There are numerous pipeline agents that look to target this underserved patient population, notably the tyrosine kinase inhibitors (TKIs) neratinib and tucatinib, as well as the HER2-targeting mAb margetuximab. However, resistance to kinase inhibitors is common, so innovative therapies to treat TKI-resistant HER2-positive disease will also be required.”
– Comments provided by Max Bourgognon, Ph.D., PharmD, Healthcare Analyst for GlobalData.
– Information based on GlobalData’s report: Pharmapoint: HER2-Positive Breast Cancer – Global Drug Forecast and Market Analysis to 2025.
– This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.
4,000 of the world’s largest companies, including over 70% of FTSE 100 and 60% of Fortune 100 companies, make more timely and better business decisions thanks to GlobalData’s unique data, expert analysis and innovative solutions, all in one platform. GlobalData’s mission is to help our clients decode the future to be more successful and innovative across a range of industries, including the healthcare, consumer, retail, financial, technology and professional services sectors.
For more information
Please get in contact if you have any questions about this or other GlobalData products. Analysts are available to comment. Contact the GlobalData press office +44 (0)161 359 5822 or email firstname.lastname@example.org.